Type 1 diabetes (T1D) is caused by
breakdowns of central and peripheral
immune tolerance and destructions of insulin-producing β-cells.
Conventional insulin injection cannot cure the disease. Regulatory
immune cells, including regulatory T-cells (Tregs) and regulatory
B-cells (Bregs), play critical roles in immune tolerance. Inducing
regulatory immune cells to halt the progress of T1D and restore immune
tolerance is the promising approach in T1D immunotherapy. Here, tetrahedral
framework nucleic acids (tFNAs) were utilized to treat T1D in non-obese
diabetic (NOD) mice. 250 nM tFNA treatment was adopted in the experiment
to reverse hyperglycemia and protect insulin-secreting β-cells
in diabetic NOD mice. In addition, 250 nM tFNA treatment could induce
Tregs and Bregs and suppress helper T (Th)-cells in the pancreas.
In the pancreas, cytokines, as a significant signal during CD4+ T-cell differentiation, directly direct the differentiation
programs. Apart from cytokines directing the differentiation of T-cells,
the signal transducer and activator of transcription (STAT) signal
is strongly associated with T-cell differentiation and T1D progression.
We demonstrated tFNA treatment inducing regulatory immune cells probably
by increasing TGF-β levels and the STAT signal. To sum up, 250
nM tFNA treatment could protect the diabetic NOD mice from hyperglycemia
and preserve the functions of β-cells by restoring peripheral
immune tolerance. The possible mechanism of inducing immune tolerance
was related to the STAT signal and cytokine changes in the pancreas.
Moreover, immunoregulation capabilities of tFNAs were demonstrated
in the experiment, which set the foundation of tFNAs participating
in further antigen-specific immunotherapies.